ZUG, Switzerland, June 01, 2023 -- Pharvaris , a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema attacks, today... | June 1, 2023
Related Keywords
Switzerland , , Pharvarisnv Stock Exchange , News , Information , Press Release , Pune , 023 , Pharvaris , Company , Developing , Mural , Antagonists , O , Treat , End , Prevent , Hereditary , Ngioedema Phvs Nl00150005y4 ,
comparemela.com © 2020. All Rights Reserved.